COVID-19 living
network meta-analysis
Drugs, antibodies, and cellular therapies for
treatment and prophylaxis against COVID-19
Drug
Treatments
Corticosteroids and interleukin-6 inhibitors probably confer important benefits in patients with severe covid-19. Janus kinase inhibitors appear to have promising benefits, but certainty is low. Azithromycin, hydroxychloroquine, lopinavir- ritonavir, and interferon-beta do not appear to have any important benefits. Whether or not remdesivir, ivermectin, and other drugs confer any patient-important benefit remains uncertain.
84
Interventions
19
outcomes
Select an intervention or specify a treatment comparison to view the summary of findings table
Prophylaxis
Hydroxychloroquine prophylaxis has trivial to no effect on hospital admission and mortality, probably increases adverse effects, and probably does not reduce the risk of SARS-CoV-2 infection. Because of serious risk of bias and very serious imprecision, it is highly uncertain whether ivermectin combined with iota-carrageenan and ivermectin alone reduce the risk of SARS-CoV-2 infection.
4
Interventions
6
outcomes
Select an intervention or specify a treatment comparison to view the summary of findings table
Antibodies &
Cellular Therapies
There is no clear effect of bamlanivimab, convalescent plasma, or IVIG on patient- important outcomes. Properly evaluating the safety and efficacy of humoral and cellular therapies for the treatment of covid-19 will requires data from additional large randomised trials.
5
Interventions
16
outcomes
Select an intervention or specify a treatment comparison to view the summary of findings table
This website provides up-to-date information about the use of pharmaceuticals, antiviral antibodies, and blood products in treatment and prevention of COVID-19. The evidence presented is the joint effort of an international group of researchers. The core group is based at McMaster University, and collaborates closely with the Magic Evidence Ecosystem Foundation and The BMJ. We also work independently of, but in collaboration with, the World Health Organization.
This work is partially funded by the Canadian Institutes of Health Research operating grants VR4-172738 and MM1-174897.
©2021 by COVID-19 Living Network Meta-Analysis Terms of Service